Table 1.
Characteristics | Total (n = 703) | |
---|---|---|
Age, years | 73 | [25‒94] |
Male, n (%) | 564 | (80.2) |
Body weight, kg, n (%) | ||
< 60 | 323 | (45.9) |
≥ 60 | 380 | (54.1) |
Time from the onset of primary HCC, years | 2.5 | [0.0‒20.6] |
< 0.5 | 135 | (19.2) |
≥ 0.5, < 1 | 65 | (9.2) |
≥ 1, < 2 | 87 | (12.4) |
≥ 2, < 3 | 69 | (9.8) |
≥ 3, < 5 | 97 | (13.8) |
≥ 5, < 10 | 121 | (17.2) |
≥ 10 | 65 | (9.2) |
Unknown | 64 | (9.1) |
ECOG PS, n (%) | ||
0 | 533 | (75.8) |
1 | 148 | (21.1) |
2 | 11 | (1.6) |
≥ 3 | 5 | (0.7) |
Unknown | 6 | (0.9) |
BCLC stage, n (%) | ||
0/A | 59 | (8.4) |
B | 291 | (41.4) |
C | 332 | (47.2) |
D | 11 | (1.6) |
Unknown | 10 | (1.4) |
Portal vein invasion, n (%) | ||
No | 520 | (74.0) |
Yes | 165 | (23.5) |
Unknown | 18 | (2.6) |
Extrahepatic lesions, n (%) | ||
No | 450 | (64.0) |
Yes | 229 | (32.6) |
Unknown | 24 | (3.4) |
Child-Pugh class, n (%) | ||
A | 624 | (88.8) |
B | 73 | (10.4) |
C | 2 | (0.3) |
Unknown | 4 | (0.6) |
Etiology, n (%) | ||
Hepatitis B virus | 137 | (19.5) |
Hepatitis C virus | 287 | (40.8) |
Alcohol | 167 | (23.8) |
NAFLD/NASH | 88 | (12.5) |
Others | 12 | (1.7) |
Unknown | 59 | (8.4) |
Treatment history, n (%) | ||
Surgerya | 227 | (32.3) |
Radiofrequency ablationb | 270 | (38.4) |
Radiation therapyc | 93 | (13.2) |
TKI therapy | 131 | (18.6) |
TACE | 513 | (73.0) |
HAIC | 74 | (10.5) |
AFP level, ng/mL, n (%) | ||
< 200 | 432 | (61.5) |
≥ 200 | 240 | (34.1) |
Unknown | 31 | (4.4) |
Data are median [min‒max] or n (%). Percentages may not add up to 100.0 because of rounding
AFP alpha-fetoprotein, BCLC stage Barcelona Clinic Liver Cancer stage, ECOG PS Eastern Cooperative Oncology Group performance status, HAIC hepatic arterial infusion chemotherapy, HCC hepatocellular carcinoma, NAFLD/NASH non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, TACE transcatheter arterial chemoembolization, TKI tyrosine kinase inhibitor
aStatus was unknown for one patient
bStatus was unknown for one patient
cStatus were unknown for two patients